BostonGene has secured top honors in five categories in the 2024 Pharmaceutical Excellence Awards – Business Expansion, Research and Development (R&D), Innovation, Product Launches and Marketing. These accolades recognize the company’s innovations and transformative contributions to the pharmaceutical industry, particularly its pivotal impact on advancing cancer care.
The Pharmaceutical Technology Excellence Awards celebrate the achievements and innovations in the pharmaceutical industry. Powered by GlobalData’s business intelligence, the Awards recognize the people and companies that are driving change in the industry.
Go deeper with GlobalData
BostonGene earned the Business Expansion award for its AI-powered platform that optimizes drug development and designs effective clinical trials on a global scale. The Product Launches award celebrates its AI digital pathology platform, reducing variability caused by manual analysis across multiple types of pathology data, improving cancer diagnostics and care. The company received the R&D award for its pioneering work on Tumor Microenvironment Typing, a comprehensive biomarker for prognosis and immunotherapy response prediction in multiple cancer types. Its immune system profiling platform, which redefines treatment predictions with a minimally invasive blood-based test, secured the Innovation award. Lastly, the Marketing award recognizes its digital expertise in promoting biopharma innovations.
Award-winning business expansion in oncology: BostonGene’s global impact
BostonGene’s strategic expansion is anchored by its AI-powered multiomics platform, which has significantly optimized drug development and clinical trial designs. By identifying multiparametric signatures and enabling the precise matching of patients with the most effective therapies, the platform has accelerated the R&D process, expanding across the US and key markets in Europe and Japan. This global presence is bringing advanced, personalized cancer care to more patients worldwide.
As a designated laboratory for the ComboMATCH trial, BostonGene is at the forefront of precision medicine, helping develop targeted drug combinations to overcome resistance to single-drug therapies. Its role in the TROP2-directed antibody-drug conjugate clinical trial with LegoChem Biosciences further solidifies its leadership in supporting clinical trials. As the central laboratory and analytic partner, BostonGene’s multiomic profiling enhances patient selection and maximizes treatment outcomes.
Revolutionizing R&D: BostonGene’s tumor microenvironment typing
BostonGene’s tumor microenvironment (TME) typing is a breakthrough in cancer research, offering a novel approach to classifying tumors based on extensive RNA sequencing data. This innovative biomarker identifies distinct TME types that influence prognosis and immunotherapy response, paving the way for more targeted and effective treatments.
The BEGIN Study with Exigent Research underscores BostonGene’s commitment to advancing molecular profiling, including tumor microenvironment typing in clinical trials. This partnership aims to validate the biomarkers’ potential in predicting immunotherapy outcomes and refining patient selection, ultimately improving cancer treatment success rates.
Innovative immune system profiling: A new frontier in oncology
BostonGene’s immune system profiling platform represents a leap forward in oncology, analyzing blood samples to predict immunotherapy response. This non-invasive method comprehensively analyzes the immune system’s potential to fight cancer, outperforming traditional biomarkers by offering a more efficient way to select patients for clinical trials and advancing the development of novel therapies.
Collaboration with the Parker Institute for Cancer Immunotherapy leverages BostonGene’s immune system profiling platform to uncover the molecular mechanisms underlying IO treatment response and treatment-related toxicity in advanced cancer patients, as well as to discover actionable blood-based biomarkers. The platform’s success in predicting responses across various cancer types sets a new benchmark in personalized cancer care, enabling more tailored and effective treatment plans for patients.
AI-based digital pathology: Transforming oncology product launches
BostonGene’s AI-based digital pathology platform has transformed the landscape of cancer diagnostics and biomarker discovery, earning the company the Product Launches award. By automating tissue analysis, the platform eliminates human error and variability, offering more reliable, standardized results in biomarker identification.
With capabilities in immunohistochemistry (IHC), hematoxylin and eosin (H&E) and multiplex immunofluorescence tests, BostonGene’s platform ensures accurate detection of established complex key biomarkers like PD-L1, tertiary lymphoid structures and tumor-infiltrating lymphocytes, and the discovery of novel signatures linked to therapy response. This biomarker detection enables personalized treatment plans and enhances prognosis accuracy, fundamentally reshaping how cancer patients’ treatments are managed.
Strategic marketing excellence: BostonGene’s digital innovation
BostonGene’s marketing strategy exemplifies digital excellence by integrating a user-centric website, a dynamic social media presence and consistent press releases to effectively communicate the latest on its AI-powered multiomics platform, collaborations, awards and more. This strategic approach has significantly bolstered the company’s brand visibility, ensuring patients, healthcare providers and the biopharma community remain well informed about the latest advancements in personalized cancer care.
Through active engagements on platforms like LinkedIn and Twitter, BostonGene has cultivated a thriving community centered around precision medicine, fostering discussions while increasing its visibility and engagement with the healthcare ecosystem. By regularly sharing updates, research findings and industry partnership news, BostonGene has solidified its position as a thought leader, maintaining a strong connection with its network and driving meaningful discussions around the future of precision medicine.
BostonGene’s innovative technologies and strategic initiatives have earned it numerous awards, reinforcing its position as a leader in precision medicine. By harnessing its AI-powered multiomics platform, the company is transforming cancer diagnostics, improving treatment predictions and enhancing patient outcomes, shaping the future of personalized medicine.
Company Profile
BostonGene is a biotechnology company specializing in advanced computational biology and precision medicine. Founded in 2015, BostonGene has consistently pushed the boundaries of innovation to improve patient care and accelerate drug development. Our AI-powered multiomics platform decodes cancer patients’ molecular profiles, including their immune system and tumor microenvironment, to uncover key disease drivers, identify novel drug targets and recommend the most effective treatments. With advanced bioanalytics, an indication-specific cancer library and a next-generation CLIA-certified, CAP-accredited high-complexity laboratory, we deliver precise, clinically validated insights that drive precision medicine and advance oncology research.
For more information, visit BostonGene at https://www.BostonGene.com.
Contact Details
University Office Park III
95 Sawyer Road, Suite 500
Waltham, MA 02453
+1 617-658-4545
Links
